Exchange: NYSE·Updated 04:00 PM EDT
RDY logo

RDYDr. Reddy's Laboratories Ltd.

$13.99
$0.50
(3.45%)
Today
EarningsJul 22
Mkt Cap$11.65B
Vol3.55M
News
all
press releases
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings callread more...
Benzinga
News Placeholder
More News
News Placeholder
Dr. Reddys Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddys Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial...
Business Wire
News Placeholder
Dr. Reddys Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif, in the United States
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and...
Business Wire
News Placeholder
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY PR Newswire NEW YORK, May 29, 2026 NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 29, 2026 /PRNewswire/ -- The New...
PR Newswire
News Placeholder
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as Dr. Reddys), a global pharmaceutical company, today announced...
Business Wire
News Placeholder
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Zacks
News Placeholder
Dr. Reddy's Laboratories (RDY) to Release Earnings on Tuesday
Dr. Reddy's Laboratories (NYSE:RDY) will be releasing its Q4 25/26 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
News Placeholder
Aikya Investment Management Ltd Has $103.03 Million Position in Dr. Reddy's Laboratories Ltd $RDY
Aikya Investment Management Ltd grew its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,338,525 shares of the...
MarketBeat
News Placeholder
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
AMPH vs. RDY: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as Dr. Reddys), a global pharmaceutical company, today announced...
Business Wire
<
1
2
...
>